chartexchange

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire Inc. | Nov 5, 2026 7:30 AM EST

RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data

Read original article